Literature DB >> 2698642

Cytotoxic T lymphocytes in HIV-induced disease: implications for therapy and vaccination.

F Plata1, G Dadaglio, N Chenciner, A Hoffenbach, S Wain-Hobson, F Michel, P Langlade-Demoyen.   

Abstract

The immune response to HIV in infected humans leads to the production of HIV-specific cytotoxic T lymphocytes (CTL) which circulate in high frequencies. The presence of these CTL and their eventual protective activities have been studied by various laboratories, and correlations have been made with certain immunopathological manifestations of HIV infections. It seems probable that HIV-immune CTL participate in the induction of certain disorders by initiating inflammatory reactions in the lungs, central nervous system and lymph nodes. Various virus antigens recognized by HIV-immune CTL on the surface of the infected cell have been identified, and molecular definition of the epitopes recognized is well under way. Likewise, numerous HLA transplantation antigens that regulate HIV antigen recognition by CTL have been identified. These data are discussed with regard to the eventual development of a vaccine and of functional immunotherapies.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2698642

Source DB:  PubMed          Journal:  Immunodefic Rev        ISSN: 0893-5300


  11 in total

Review 1.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

Review 2.  Role of class I molecules of the major histocompatibility complex in cytotoxic T-cell function in health and disease.

Authors:  A J McMichael
Journal:  Springer Semin Immunopathol       Date:  1992

3.  HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals.

Authors:  A Achour; O Picard; D Zagury; P S Sarin; R C Gallo; P H Naylor; A L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

4.  Specific lysis of human immunodeficiency virus type 1-infected cells by a HLA-A3.1-restricted CD8+ cytotoxic T-lymphocyte clone that recognizes a conserved peptide sequence within the gp41 subunit of the envelope protein.

Authors:  K Takahashi; L C Dai; T R Fuerst; W E Biddison; P L Earl; B Moss; F A Ennis
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

5.  Relation of HIV-I in bronchoalveolar lavage cells to abnormalities of lung function and to the presence of Pneumocystis pneumonia in HIV-I seropositive patients.

Authors:  J R Clarke; I K Taylor; J Fleming; J D Williamson; D M Mitchell
Journal:  Thorax       Date:  1993-12       Impact factor: 9.139

6.  Induction of feline immunodeficiency virus-specific cytotoxic T cells in vivo with carrier-free synthetic peptide.

Authors:  J N Flynn; C A Cannon; J A Beatty; M Mackett; M A Rigby; J C Neil; C Jarrett
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

7.  Ovine lentivirus is macrophagetropic and does not replicate productively in T lymphocytes.

Authors:  M D Gorrell; M R Brandon; D Sheffer; R J Adams; O Narayan
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

8.  Bone marrow transplantation therapy using resistant donors for retrovirus-induced leukaemia in mice.

Authors:  H Iwai; N K Day; N Hamada; M M Inaba; S Ikehara; R A Good
Journal:  Clin Exp Immunol       Date:  1994-01       Impact factor: 4.330

9.  Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine.

Authors:  S K Kundu; D Katzenstein; L E Moses; T C Merigan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

10.  Recognition of a highly conserved region of human immunodeficiency virus type 1 gp120 by an HLA-Cw4-restricted cytotoxic T-lymphocyte clone.

Authors:  R P Johnson; A Trocha; T M Buchanan; B D Walker
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.